Our most recent white paper discusses the results of running the Olink Explore HT assay on both the Illumina NovaSeq X Plus and the Ultima Genomics UG 100. Explore HT is a multiplex protein assay, capable of targeting over 5,400 proteins in a single panel. The assay offers 99.5% specificity and 100% coverage of top-level pathways.
The purpose of this white paper was to assess the efficiency and accuracy of the UG 100 in running Olink Proteomics projects. The recent launch of the UG 100 and its “flow-based” technology has created a new option for less expensive, low-error next-generation sequencing. To test this, our lab sequenced the same four Explore HT libraries on the UG 100 and on the NovaSeq X Plus.
Our bioinformatics team then compared the runs on Illumina and Ultima instruments. Results showed:
-
Comparable distribution of total counts per sample
-
Comparable distribution of total counts per platform
-
Strong correlation between samples
-
High reproducibility between platforms
-
Consistent protein abundance across runs
-
Sequencing batch effects successfully removed via bridging
These results indicate that the Ultima Genomics UG 100 generates data comparable in quality to the Illumina NovaSeq X Plus, but is a more cost-effective choice for sequencing. For more details and data, read the full white paper at the link below.
About Psomagen
Psomagen, Inc., formerly Macrogen U.S.A., is a North American integrative omics solutions and contract laboratory services provider. The company makes cutting-edge technology and data analysis accessible to the academic, pharma, biotech and clinical markets. With both CLIA-certified and CAP-accredited facilities, its team delivers the highest-quality multiomics data using best-in-class DNA, RNA, and protein analysis systems. In conjunction with its bioinformatics capabilities, Psomagen offers a path to insights that is both simple and affordable. Learn more at psomagen.com.
About Ultima Genomics
Ultima Genomics mission is to continuously drive the scale of genomic information to enable unprecedented advances in biology and improvements in human health. Ultima is challenging conventional next-generation sequencing technologies, with its new sequencing architecture designed to scale far beyond conventional sequencing technologies, lower the cost of genomic information and catalyze the next phase of genomics in the 21st century. To learn more, visit www.ultimagenomics.com.
